世界卫生组织第三组肺高血压中血管活性和死亡率的前性分析
Daniel J Strick1, Carl Tanba1, Meredith A Kaplan1
1Tufts Medical Center Boston Massachusetts USA.
第三组肺高血压 (PH) 的预后标志物尚不清楚. 在血管活性测试期间肺血管阻力 (PVR) 降低表明3组PH患者的死亡风险较高.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 医学研究 医学研究
背景情况:
- 第三组肺高血压 (PH) 的预后标志物尚未得到充分确立.
- 了解患者个人资料和潜在的预后工具对于这一群体至关重要.
研究的目的:
- 为了分析3组PH患者的情况.
- 评估血管活性测试作为预后工具在3组PH.
- 测试一个更强的血管收缩成分预测更好的预后的假设.
主要方法:
- 对3组PH患者的临床数据评估.
- 在右心导管治疗期间,吸入氧化的施用.
- 评估欧洲呼吸学会关于血管活性测试的指导方针 (如第1组PAH的定义).
主要成果:
- 在平均肺动脉压 (mPAP) 和生存率的变化之间没有发现显著的关系.
- 血管扩张期间肺血管抵抗 (PVR) 的较大降低与死亡风险显著增加相关.
- 在急性血管扩张器挑战期间PVR的变化可能是与mPAP相比,3组PH中更好的生存指标.
结论:
- 血管活性测试,特别是PVR的变化,可以作为3组PH的预后指标.
- 血管活性的预后影响在1组PAH和3组PH之间有所不同.
- 需要进一步的研究来完善3组PH的预后标志物.
更多相关视频
07:41A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
Published on: March 1, 2022
08:12Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS
Published on: November 26, 2018
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Vascular Resistance
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Vasodilators
Measurement of Blood Pressure
